Managers and reps

Quote









anonymous said:
Just hiring their friends and ex-Allergan people. Amazing when some of the top spots are filled by people who didn’t qualify for them.
Click to expand...

Just another dump that will be sold off in a year or two. I’ve never seen a larger group of eyecare misfits in one place. Hopefully, the first line leaders are better than the senior leadership.
 














anonymous said:
Hiring has nothing to do with how promising an organization will be. Explain that one to me.
Click to expand...

I really need to explain myself? grow up. The people and leadership team they hire helps create and or maintains a companies culture. That has a huge role on the organization. Their culture seems great so far. And yes the product seems very promising along with the pipeline.
 


anonymous said:
I really need to explain myself? grow up. The people and leadership team they hire helps create and or maintains a companies culture. That has a huge role on the organization. Their culture seems great so far. And yes the product seems very promising along with the pipeline.
Click to expand...

I already work here. The culture is not what it seems. The people that they hired so far are a disaster. Horrible Regional dope that has no clue how to tie his shoes. The marketing department is made up of kiss arses that treat people like cr*p. I’m already looking for another job. Let’s just see how easy the product will be to prescribe.
 


Think it’s going to be an uphill battle, it can be done, they have some good people there. They need expedited demand within the first 3-5 months or they’ll run out of cash within 12-15 months. This will lead down 3 paths, raise money through stock which will dilute the stock, or borrow money, unlikely given the nature of the economy/inflation and interest rates. Or hope to get sold, who’s really buying? Look at the last several eyecare surface launches, Xiidra (lost money for before making money), Cequa (took 3 years to get a small foothold, w a gross guesstimate of 30-50million), Eyesuvis, bankrupt and sold for 50 million. Good chance they’ll run out of money, hope not, the market for stand alone startups, successfully commercializing isn’t good, unless you’re in rare like dompe. Coverage and how much a patient is worth per Rx matters. Best of luck
 


I was all about this company but the more people I talk to, the less desirable this place looks.

anonymous said:
Think it’s going to be an uphill battle, it can be done, they have some good people there. They need expedited demand within the first 3-5 months or they’ll run out of cash within 12-15 months. This will lead down 3 paths, raise money through stock which will dilute the stock, or borrow money, unlikely given the nature of the economy/inflation and interest rates. Or hope to get sold, who’s really buying? Look at the last several eyecare surface launches, Xiidra (lost money for before making money), Cequa (took 3 years to get a small foothold, w a gross guesstimate of 30-50million), Eyesuvis, bankrupt and sold for 50 million. Good chance they’ll run out of money, hope not, the market for stand alone startups, successfully commercializing isn’t good, unless you’re in rare like dompe. Coverage and how much a patient is worth per Rx matters. Best of luck
Click to expand...
 





Write your reply...
Top Bottom
Back
Quote